Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib Basket Trial of Mobocertinib + T-DM1 in HER2-Mutant Solid Tumors (WJOG16022M)
jRCT2051220070Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mobocertinib and trastuzumab emtansine in Nonhematologic neoplasms, Bone and soft tissue sarcoma and cancer (2 arms), sponsored by Takeda. Primary endpoint: Objective response rate. Started Nov 2022; status: active, not recruiting.
02
Drugs
mobocertinibtrastuzumab emtansine
03
Conditions
Nonhematologic neoplasmsBone and soft tissue sarcomacancer
Beyond the preview
Go deeper on jRCT2051220070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220070.